Invivyd Inc (IVVD)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Infectious Diseasesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 40/100 (MEDIUM), 12.5 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 15.8% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
- Invivyd’s Covid-directed mAb hits Phase III safety goals
- Invivyd Reports Positive Phase 3 LIBERTY Results for VYD2311 and Plans Accelerated Approval Submission
- Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Invivyd to Participate in Upcoming September Investor Conferences
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial. — Lancet Infect Dis 2026 Aug 31 PMID 42673984
- Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma. — J Immunother Cancer 2026 Jul 7 PMID 42413982
- Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial. — Lancet HIV 2026 May PMID 42067280
- Multicenter Evaluation of Ceftazidime/Avibactam in Pediatric Patients Across the United States: Real-World Insights into the Management of Drug-Resistant Gram-Negative Infections. — Open Forum Infect Dis 2026 Apr PMID 42016367
- Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis. — Lancet HIV 2026 May PMID 41936375
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Invivyd Inc.
Full IVVD Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.